Literature DB >> 19331805

Graves' disease treated with thyroid arterial embolization.

Wei Zhao1, Bu-Lang Gao, Min Tian, Gen-Fa Yi, Hui-Ying Yang, Li-Juan Shen, Hong Li, Jin Shen.   

Abstract

PURPOSE: To study pathological changes in the thyroid gland of patients with Graves' disease (GD) treated with thyroid arterial embolization.
METHODS: Thirty-seven patients with GD were treated through transcatheter thyroid arterial embolization. Of these patients, twenty-two had biopsy of the thyroid gland at different time points before and after the embolization for the study of pathology. Serum thyroid hormones, TSH and TRAb were also studied at these time points. Thyroid size was evaluated in all patients using color Doppler ultrasound or CT scan.
RESULTS: Thyroid size decreased immediately or several days following embolization. Pathological study demonstrated mainly acute infarction and necrosis at 7 days post embolization. At 6 months, chronic inflammation and fibrous hyperplasia were the primary findings in the gland, and at 3 years following embolization, mesenchyma hyperplasia and follicle atrophy were primarily present in the embolized thyroid tissue. The thyroid hormones and TSH gradually resumed to normal range after embolization while TRAb decreased significantly.
CONCLUSION: Thyroid arterial embolization can cause GD thyroid gland a series of pathological changes of acute ischemia and necrosis and later, chronic inflammation, fibroplasia and atrophy to decrease secretion of thyroid. The pathological changes within the thyroid gland after embolization form the basis of thyroid arterial embolization in treating GD hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331805     DOI: 10.25011/cim.v32i2.6034

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  4 in total

1.  [Update hyperthyreoidism].

Authors:  L Möller; K Mann
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

2.  Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.

Authors:  Iraj Nabipour; Mohammadreza Kalantarhormozi; Majid Assadi; Seyed Mojtaba Jafari; Mohammad Gharibi; Esmaeil Ahmadi; Zahra Sanjdideh
Journal:  Endocrine       Date:  2010-11-02       Impact factor: 3.633

3.  Changes associated with percutaneous ethanol injection in the treatment of thyroid nodules.

Authors:  Gianna Carla Alberti Schrut; Fabíola Yukiko Miasaki; Gilberto Paz-Filho; Teresa Cristina Santos Cavalcanti; Hans Graf; Gisah Amaral de Carvalho
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

4.  The calcium-phosphate balance, modulation of thyroid autoimmune processes and other adverse effects connected with thyroid arterial embolization.

Authors:  Grzegorz Kaminski; Andrzej Jaroszuk; Ariadna Zybek; Krzysztof Brzozowski; Piotr Piasecki; Piotr Ziecina; Marek Ruchala
Journal:  Endocrine       Date:  2013-10-22       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.